{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:48:20Z","timestamp":1756075700145},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.bjid.2016.09.009","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T08:00:39Z","timestamp":1478332839000},"page":"79-87","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Antifungal pharmacodynamics: Latin America's perspective"],"prefix":"10.1016","volume":"21","author":[{"given":"Javier M.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Agudelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres F.","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Vesga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2016.09.009_bib0400","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2012.06.012","article-title":"The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012","volume":"73","author":"Azie","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0405","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/342300","article-title":"Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989\u20131999","volume":"35","author":"Trick","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0410","doi-asserted-by":"crossref","first-page":"e59373","DOI":"10.1371\/journal.pone.0059373","article-title":"Epidemiology of candidemia in Latin America: a laboratory-based survey","volume":"8","author":"Nucci","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bjid.2016.09.009_bib0415","first-page":"785","article-title":"Epidemiology of endemic systemic fungal infections in Latin America","volume":"49","author":"Colombo","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.bjid.2016.09.009_bib0420","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.idc.2010.11.003","article-title":"Nosocomial fungal infections: epidemiology, infection control, and prevention","volume":"25","author":"Alangaden","year":"2011","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.bjid.2016.09.009_bib0425","doi-asserted-by":"crossref","first-page":"e101510","DOI":"10.1371\/journal.pone.0101510","article-title":"Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004\u20132008","volume":"9","author":"Pfaller","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bjid.2016.09.009_bib0430","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0435","first-page":"175","article-title":"Epidemiology and treatment approaches in management of invasive fungal infections","volume":"3","author":"Kriengkauykiat","year":"2011","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.bjid.2016.09.009_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.bjid.2016.09.009_bib0445","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/518137","article-title":"Pharmacokinetics and pharmacodynamics of antimicrobials","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0450","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.me.27.020176.001443","article-title":"Significance of serum protein and tissue binding of antimicrobial agents","volume":"27","author":"Craig","year":"1976","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bjid.2016.09.009_bib0455","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","volume":"24","author":"Rex","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0460","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0465","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A3","author":"CLSI","year":"2008"},{"key":"10.1016\/j.bjid.2016.09.009_bib0470","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/34.1.83","article-title":"The postantibiotic effect of antifungal agents against common pathogenic yeasts","volume":"34","author":"Turnidge","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0475","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jac\/dkh066","article-title":"A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans","volume":"53","author":"Manavathu","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0485","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0490","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0495","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","article-title":"Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity","volume":"49","author":"Louie","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0500","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0505","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00296-07","article-title":"Correlation of the MIC and dose\/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia","volume":"51","author":"Rodriguez-Tudela","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0510","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1128\/AAC.00116-08","article-title":"Association of fluconazole pharmacodynamics with mortality in patients with candidemia","volume":"52","author":"Baddley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0515","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.44.4.1108-1111.2000","article-title":"Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans","volume":"44","author":"Ernst","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0520","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/AAC.50.2.469-473.2006","article-title":"Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"50","author":"Wiederhold","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0525","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0530","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.04723-14","article-title":"Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus","volume":"59","author":"Al-Nakeeb","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.bjid.2016.09.009_bib0535","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1093\/clinids\/22.Supplement_2.S145","article-title":"Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials","volume":"22","author":"Gallis","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0540","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","article-title":"Amphotericin B pharmacokinetics in humans","volume":"13","author":"Atkinson","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0545","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0550","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0555","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","article-title":"Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies","volume":"41","author":"Adedoyin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0560","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0565","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0570","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dku148","article-title":"Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B","volume":"69","author":"Strenger","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0575","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0580","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0585","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","article-title":"A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei","volume":"41","author":"Sanati","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.bjid.2016.09.009_bib0590","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1439-0507.2006.01295.x","article-title":"A new, broad-spectrum azole antifungal: posaconazole \u2013 mechanisms of action and resistance, spectrum of activity","volume":"49","author":"Hof","year":"2006","journal-title":"Mycoses"},{"key":"10.1016\/j.bjid.2016.09.009_bib0595","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.42.5.1105","article-title":"Pharmacodynamics of fluconazole in a murine model of systemic candidiasis","volume":"42","author":"Louie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0600","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bjid.2016.09.009_bib0605","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.3.4.573","article-title":"CNS pharmacokinetics of antifungal agents","volume":"3","author":"Kethireddy","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bjid.2016.09.009_bib0610","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1128\/AAC.01053-05","article-title":"Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0615","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1128\/AAC.01305-05","article-title":"In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0620","series-title":"Standardization of a murine model of Candida albicans infection to study therapeutic equivalence (TE) of fluconazole (FCZ) generics","year":"2012"},{"key":"10.1016\/j.bjid.2016.09.009_bib0625","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0630","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0635","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-S4","author":"CLSI","year":"2012"},{"key":"10.1016\/j.bjid.2016.09.009_bib0640","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1128\/AAC.00606-10","article-title":"Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis","volume":"54","author":"Mavridou","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0645","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/AAC.01279-12","article-title":"Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0650","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0655","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1128\/AAC.01396-09","article-title":"Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients","volume":"54","author":"Conte","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0660","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0665","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0670","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0675","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0680","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0685","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0690","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0695","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1111\/j.1469-0691.2012.03890.x","article-title":"EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2016.09.009_bib0700","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/AAC.00496-15","article-title":"Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension","volume":"59","author":"Durani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0705","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/AAC.00478-08","article-title":"In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0710","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/424465","article-title":"Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity","volume":"190","author":"Wiederhold","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bjid.2016.09.009_bib0715","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/jac\/dkn069","article-title":"Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"61","author":"Lewis","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0720","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1128\/AAC.00507-06","article-title":"Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis","volume":"50","author":"Gumbo","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0725","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1128\/AAC.48.9.3407-3411.2004","article-title":"Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations","volume":"48","author":"Stevens","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0730","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/AAC.00999-10","article-title":"Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum","volume":"55","author":"Shields","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0735","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkq545","article-title":"Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration","volume":"66","author":"Leitner","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0740","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.01901-07","article-title":"In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2016.09.009_bib0745","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0750","series-title":"Clinical breakpoints for Candida and the echinocandins. Subcommittee on antifungal susceptibility tests","author":"CLSI","year":"2010"},{"key":"10.1016\/j.bjid.2016.09.009_bib0755","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2016.09.009_bib0760","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2016.09.009_bib0765","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/JCM.00566-08","article-title":"Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2016.09.009_bib0770","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0775","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40265-014-0227-3","article-title":"Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications","volume":"74","author":"Autmizguine","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bjid.2016.09.009_bib0780","first-page":"179","article-title":"Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network","volume":"30","author":"Nucci","year":"2013","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.bjid.2016.09.009_bib0785","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2016.09.009_bib0790","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Therap Drug Monit"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867016304342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867016304342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T09:26:55Z","timestamp":1568539615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867016304342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1413867016304342"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2016.09.009","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal pharmacodynamics: Latin America's perspective","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2016.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}